Jurgen Dittmer
Overview
Explore the profile of Jurgen Dittmer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
1051
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dittmer A, Dittmer J
Cancers (Basel)
. 2022 Oct;
14(20).
PMID: 36291767
TIMP-1 is one of the many factors that CAFs have been shown to secret. TIMP-1 can act in a tumor-supportive or tumor-suppressive manner. The purpose of this study was to...
2.
Dittmer J
Front Endocrinol (Lausanne)
. 2022 Sep;
13:983793.
PMID: 36093095
The insulin-like growth factor receptor (IGF1R) pathway plays an important role in cancer progression. In breast cancer, the IGF1R pathway is linked to estrogen-dependent signaling. Regulation of IGF1R activity is...
3.
Czapiewski P, Cornelius M, Hartig R, Kalinski T, Haybaeck J, Dittmer A, et al.
Virchows Arch
. 2022 Jan;
480(3):529-541.
PMID: 35020071
Patients with estrogen receptor positive breast cancer are usually receiving an anti-estrogen therapy by either aromatase inhibitors or selective estrogen receptor mediators such as tamoxifen. Nevertheless, acquired resistance to tamoxifen...
4.
Dittmer J
Front Oncol
. 2021 Oct;
11:736597.
PMID: 34604071
Endocrine therapy is a standard treatment offered to patients with ERα (estrogen receptor α)-positive breast cancer. In endocrine therapy, ERα is either directly targeted by anti-estrogens or indirectly by aromatase...
5.
Dittmer A, Dittmer J
Cancers (Basel)
. 2020 Nov;
12(11).
PMID: 33228022
CAFs (Carcinoma-associated fibroblasts) play an important role in cancer progression. For instance, they promote resistance to anti-estrogens, such as fulvestrant. Here, we show that, in ERα-positive breast cancer cell lines,...
6.
Dittmer A, Lange T, Leyh B, Dittmer J
Int J Oncol
. 2019 Dec;
56(1):258-272.
PMID: 31789400
Carcinoma‑associated fibroblasts (CAFs) secrete factors that increase the expression and/or activities of proteins in breast cancer cells and induce resistance to anti‑estrogens, such as fulvestrant. A major factor is interleukin‑6...
7.
Dittmer J
Semin Cancer Biol
. 2018 Jul;
53:59-74.
PMID: 30059727
The current view is that breast cancer is a stem cell disease characterized by the existence of cancer cells with stem-like features and tumor-initiating potential. These cells are made responsible...
8.
Dittmer A, Dittmer J
Oncotarget
. 2018 May;
9(31):22079-22094.
PMID: 29774124
We studied the long-term effect of stromal factors on the development of fulvestrant-resistance (FR) and fulvestrant-induced dormancy (D). Sublines established from stroma-treated FR-cells (C-FR cells) and D-cells (C-D cells) show...
9.
Dittmer J
Semin Cancer Biol
. 2017 Mar;
44:72-82.
PMID: 28344165
Breast cancer is a systemic disease characterized by early dissemination of tumor cells to distant organs. In this foreign environment, tumor cells may stay in a dormant state as single...
10.
Nass N, Dittmer A, Hellwig V, Lange T, Beyer J, Leyh B, et al.
Oncotarget
. 2016 May;
7(25):38408-38426.
PMID: 27224909
We have previously shown that stromal cells desensitize breast cancer cells to the anti-estrogen fulvestrant and, along with it, downregulate the expression of TMEM26 (transmembrane protein 26). In an effort...